Olaparib:a new drug for hereditary ovarian cancer treatment / 药学实践杂志

ABSTRACT

Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes ,and was developed by AstraZen-eca Pharmaceuticals LP .Olaparib has therapeutic potential for treating cancers associated with impaired DNA repair capabili-ties ,particularly those with deficiencies in the homologous recombination repair (HRR) pathway .Olaparib is an available ther-apy option for ovarian cancer patients with deficiencies in the BRCA 1 and BRCA2 genes .Olaparib can selectively kill cancer cells without compromising normal cells .Compared to traditional chemotherapy means ,adverse reactions are much smaller .